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epidemiology of the speciﬁ c disease, the adoption and diffusion rate of new drug, etc. 
Drug cost is expressed as the monthly cost of new and/or existing drugs. Treatment 
duration is the average months of patient remained on new and/or existing drugs 
which could be derived from clinical trials or clinical observations. Person-time on 
treatment is calculated by multiplying (1) and (2) and be allocated to respective budget 
year, then multiple (3) to obtain the annual cost of new and/or existing treatment. 
The net ﬁ nancial impact is the annual cost difference between new and existing treat-
ment. CONCLUSIONS: The framework is simple and ﬂ exible, feasible for most new 
drug applications to estimate likely ﬁ nancial impact. It has been adopted by recently 
revised new drug reimbursement application form of NHI. The working tool is freely 
available as an option for calculation. 
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OBJECTIVES: The objectives of this study were to develop the relative value units 
(RVUs) and unit costs of hospital health services employing the RVU method for 
economic evaluation in Thailand. METHODS: The RVUs were developed by using 
the objective data method based on the reimbursable price list of the Civil Service 
Medical Beneﬁ t Scheme. For non-reimbursable health promotion and prevention 
services, unit costs were calculated at a selected hospital for RVU development. To 
test the RVUs, the unit costs calculated by RVU method were compared to those 
computed by conventional micro-costing method. Then, the RVUs were used to cal-
culate standard unit costs of health services. Three district hospitals and three provin-
cial hospitals where met the developed efﬁ ciency criteria were selected for the 
calculation. Total hospital cost including labor, material and capital costs and exclud-
ing pharmacy cost was calculated. Total RVUs were calculated by the summation of 
the multiplication of number of health services provided and its RVU. Total cost was 
divided by the total RVUs resulting in cost per RVU. Finally, unit cost of each service 
was calculated by the multiplication of number of RVUs and cost per RVU. RESULTS: 
This study results in RVUs of 3091 health service items which were classiﬁ ed into 12 
groups. Unit cost of each service classiﬁ ed by types of hospitals was provided. A web-
based standard unit cost list was created and could be accessible to the public. 
CONCLUSIONS: This study developed the ﬁ rst list of standard unit cost of health 
services of district and provincial hospitals in Thailand. The standard unit cost list is 
an important tool for providing cost inputs when performing economic evaluation of 
health interventions and it helps standardize and improve the quality of economic 
evaluation studies in Thailand. 
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OBJECTIVES: The use of statin has been shown to be cost effective in the secondary 
prevention of coronary heart disease and cerebrovascular disease. However, a “treat-
ment gap” exists, whereby many eligible patients do not receive statin therapy. We 
sought to determine the cost-effectiveness of closing this treatment gap in the Austra-
lian healthcare setting. METHODS: Analysis was based on 4-year follow-up data from 
Australian participants of the Reduction of Atherothrombosis for Continued Health 
(REACH) Registry. Subjects were aged 345 years and had established atherothrom-
botic disease, comprising coronary artery disease (CAD), and cerebrovascular (CerVD) 
disease. Decision analysis was applied to compare current coverage with statin against 
a hypothetical situation whereby all subjects were assumed to be treated. Outcomes 
of interest were nonfatal stroke, nonfatal myocardial infraction (MI), and cardiovas-
cular deaths. The relative changes to the risks of these outcomes conferred by statin 
were derived from published meta-analysis. Costs were based on government-reim-
bursed data for 2009. RESULTS: Among the sample of 2768 participants, coverage 
with statin therapy was between 63% and 82%, depending on age group. Over the 
4-year period, 89, 101, and 146 nonfatal strokes, nonfatal MIs, and cardiovascular 
deaths were observed, respectively. Assuming that all subjects had taken statin, the 
predicted equivalent numbers were 85, 96, and 137 respectively. The estimated incre-
mental cost-effectiveness ratio (ICER) for CAD subjects was AUD $45,274 per life-
year gained (LYG). For CerVD subjects, the ICERs were AUD $40,738. Equating to 
numbers needed to treat of 136 and 99.5. Sensitivity analysis showed that the results 
were robust. CONCLUSIONS: The results of this model suggest that for subjects with 
athethrombotic disease, maximizing coverage with statin, in line with evidence-based 
recommendations, represents a cost-effective means of secondary prevention. 
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OBJECTIVES: Patients receiving enoxaparin are at risk of bleeding. However, the 
study of the ﬁ nancial impact of enoxaparin-associated bleeding is limited. This study 
aims to estimate the attributable costs and length of stay (LOS) of patients with 
enoxaparin-associated bleeding (EAB) compared with non-bleeding patients (NB). 
METHODS: We conducted a retrospective cohort study of hospitalized acute coro-
nary syndrome patients who received enoxaparin since January 2006 to February 
2009 in a large University-afﬁ liated hospital. Cost and LOS were compared between 
patients with and without EAB on both univariable and multivariable analyses. In 
multivariable analysis, the attributable cost and LOS were estimated using a multiple 
linear regression with log-transformed model and adjusted by propensity score (PS), 
which was predicted by patient’ characteristics including age, gender, history of bleed-
ing, hypertension, stroke, diabetes, creatinine clearance, and congestive heart failure 
(CHF) at admission. The adjusted means of cost and LOS estimates were retrans-
formed to their natural values using Duan’s smearing estimator. The differences of 
costs and LOS were presented as mean with 95% conﬁ dence intervals. RESULTS: 
Out of 346 patients, 134 (38.7%) experienced enoxaparin-associated bleeding. The 
average age and comorbidities in both groups were similar. However, in EAB group 
had more male than NB group (42% vs. 30%). Based on univariable analyses, the 
attributable cost and LOS of patients with EAB were 68,875 THB ($2152) and 4.2 
days, respectively. Based on PS-adjusted multivariable regression analyses, the cost 
and LOS attributable to EAB was 80,644 THB ($2520) (95% CI: 69,879 ($2184) to 
91,408 ($2857) and 3.4 days (95% CI: 3.0 to 3.7), respectively. CONCLUSIONS: 
Bleeding is associated with increased cost and LOS among enoxaparin users. These 
ﬁ ndings suggest that strategies that reduce the risk of bleeding have the potential 
important reductions in costs of care for enoxaparin users. 
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OBJECTIVES: To evaluate the cost-effectiveness of rivaroxaban against enoxaparin 
for prevention of venous thromboembolism (VTE) following total knee replacement 
(TKR) in China. METHODS: An economic model was developed, consisting of three 
modules: prophylaxis, post-prophylaxis, and long-term complications. The ﬁ rst two 
modules were represented using a decision tree while the third module used a Markov 
process. Safety and efﬁ cacy data during prophylaxis were derived from a Phase III inter-
national multi-regional registration trail (RECORD 3). Utility outcomes and the probabil-
ity of long-term events were based on systematic review and published data. Resource use 
related to VTE prevention, treatment and complications was based on clinical guidelines, 
product labels, and interviews conducted in six Tier 3 hospitals in Beijing, Shanghai and 
Guangzhou City. Unit cost data were collected from government pricing bureau and 
presented in 2009 CNY from the health-care system perspective. Costs and outcomes were 
discounted at 3% per annum. Extensive one-way probabilistic sensitivity analyses were 
undertaken. RESULTS: In the base case analyses, rivaroxaban was shown to be domi-
nant compared with enoxaparin. Rivaroxaban was associated with 0.0019 additional 
QALYs per patient while saving an average of CNY 242 per patient over 5 years. 
Costs associated with VTE clinical events were lower in rivaroxaban group (CNY 
581) compared with the enoxaparin group (CNY 1059). Probabilistic sensitivity 
analyses estimated that rivaroxaban had a probability of >90% of being cost-effective 
compared with enoxaparin at a low willingness-to-pay threshold of CNY 20,000 per 
QALY gained. CONCLUSIONS: Compared with enoxaparin, rivaroxaban improved 
patients’ health outcomes and produced overall cost savings in VTE prevention after 
TKR in China. 
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OBJECTIVES: This systematic review was conducted for The New Zealand Ministry 
of Health to summarize recent evidence pertaining to the clinical effectiveness of 
64-slice or higher computed tomography angiography (CTA) in patients with sus-
pected coronary artery disease (CAD). If CTA proves to be a successful diagnostic 
performance measure, it could prevent the application of invasive diagnostic proce-
dures in some patients. This would provide multiple health and cost beneﬁ ts, particu-
larly for under resourced District Health Boards where invasive coronary angiography 
is not always available. METHODS: A systematic method of literature searching and 
selection was employed with searches limited to December 2006 to March 2009. 
Included studies were quality assessed using NHMRC diagnostic levels of evidence 
and a modiﬁ ed QUADAS tool. Individual and pooled diagnostic performance mea-
sures (i.e., sensitivity, speciﬁ city, positive predictive value (PPV), negative predictive 
